Patient-reported tolerance of 90 days of preoperative endocrine therapy: results from the preoperative window of endocrine therapy to inform radiation therapy decisions trial
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf172 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Trish Millard und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Virginia, Charlottesville, VA, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, American Cancer Society Institutional Research, NIH HHS.
Abstract (Originalsprache)
Background
Prospective randomized data supports radiation omission in women ≥65 years who take adjuvant endocrine therapy (AET) following breast-conserving surgery. Many patients who omit radiation stop AET early due to side effects. In the POWER trial, a prospective single-arm study, patients took 90 days of preoperative endocrine therapy (pre-ET) to assess tolerance before making adjuvant treatment decisions. We hypothesized that patient-reported outcomes (PROs) during pre-ET would be heterogeneous and that 90 days was sufficient time for symptoms to develop. Patients and Methods PRO data from POWER trial participants was obtained before, during, and after pre-ET, including health-related quality of life (HRQoL), depression, and ET symptoms using the EORTC-QLQ, CESD-R, and BCPT-SCL tools. PRO assessments were further analyzed after stratifying patients by high or low perceived sensitivity to medicine (PSM).
Results
Pre-ET PROs were assessed for 75 participants. The majority (73.3%) reported symptoms during pre-ET. Only 10.7% had symptoms severe enough to stop pre-ET before 90 days. Vasomotor (42.7%) and musculoskeletal (41.3%) symptoms were the most common. HRQoL was preserved for 66.6% of participants. Patients with high PSM had more ET side effects.
Conclusions
Patients developed similar side effects during pre-ET as those typically seen with AET. PROs and the impact of pre-ET on HRQoL were patient-dependent. A 90-day course of pre-ET is sufficient for patients to develop symptoms reflective of long-term AET. Future analyses will assess the association of pre-ET PROs with AET initiation and adherence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Virginia, Charlottesville, VA, USA.
- Department of Surgery, University of Virginia, Charlottesville, VA, USA.
- Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.
ORCID-Profile: Trish Millard
Förderung
- NCI NIH HHS
- American Cancer Society Institutional Research
- NIH HHS
- National Institutes of Health
Zitieren
APA
Millard, T., Turkheimer, L. M., Schlefman, J., Petroni, G. R., Brighton, D., & Showalter, S. L. (2025). Patient-reported tolerance of 90 days of preoperative endocrine therapy: results from the preoperative window of endocrine therapy to inform radiation therapy decisions trial. The Oncologist. https://doi.org/10.1093/oncolo/oyaf172
Vancouver
Millard T, Turkheimer LM, Schlefman J, Petroni GR, Brighton D, Showalter SL. Patient-reported tolerance of 90 days of preoperative endocrine therapy: results from the preoperative window of endocrine therapy to inform radiation therapy decisions trial. The Oncologist. 2025. doi:10.1093/oncolo/oyaf172
BibTeX
@article{Millard2025,
author = {Millard, Trish and Turkheimer, Lena M and Schlefman, Jenna and Petroni, Gina R and Brighton, David and Showalter, Shayna L},
title = {Patient-reported tolerance of 90 days of preoperative endocrine therapy: results from the preoperative window of endocrine therapy to inform radiation therapy decisions trial},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf172}
}
EUVIMED